surrogate virus neutralising test genscript cpass sars-cov-2  (GenScript corporation)

Journal: PLOS Pathogens

Article Title: Characterisation of the antibody-mediated selective pressure driving intra-host evolution of SARS-CoV-2 in prolonged infection

doi: 10.1371/journal.ppat.1012624

Figure Lengend Snippet: Peripheral blood samples obtained from the patient on the days indicated were tested by the quantitative Abbott Anti-RBD-CMIA (a) and the GenScript cPass sVNT (b) . Antibody levels detected by Anti-RBD-CMIA and sVNT are given as arbitrary units (AU)/mL, cut-off ≥50 AU/mL, and signal reduction (% inhibition, cut-off >30%) as compared to the negative control. The GenScript cPass sVNT was performed with technical duplicates at a serum dilution of 1:20. The cut-off of the sVNT is indicated by the horizontal dotted line. (c) Qualitative results of the Mikrogen line blot testing for Anti-N IgG, as well as Anti-S1 and Anti-RBD IgM and IgG, are indicated as follows: open squares: non-reactive, grey squares: reactive below cut-off, black squares: reactive above cut-off. Administration of bamlanivimab (B), first vaccination (V) and therapy with sotrovimab (S) is indicated by vertical dotted lines.

Article Snippet: The commercial surrogate virus neutralisation test cPass (GenScript Biotech) was used to quantify levels of antibodies inhibiting the binding of the RBD to ACE2 [ , ].

Techniques: Inhibition, Negative Control